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Islets secretory capacity determines glucose homoeostasis in the
face of insulin resistance
Abstract
BACKGROUND: Debate surrounds the relative importance of impaired beta-cell secretory function
versus insulin resistance in type 2 diabetes. We therefore defined insulin secretion and sensitivity in
patients with impaired glucose homoeostasis of varying aetiology and duration. METHODS: 126
consecutive patients undergoing an oral glucose tolerance test (OGTT) between 1999 and 2003 were
included. Whole-body insulin sensitivity index (ISI) and insulinogenic index derived from the OGTT
were determined in 32 healthy controls, 65 type 2 diabetic patients, 15 patients with acromegaly, 10
patients with insulinoma, and 4 patients with HAIRAN syndrome. RESULTS: Median ISI (quartiles
Q25-Q75) of healthy controls and of patients with insulinoma were similar (3.5 [2.8-5.6] and 3.2
[1.7-4.2] respectively) but significantly decreased in patients with acromegaly, type 2 diabetes, and
HAIRAN syndrome (2.8 [1.8-3.3], 1.9 [1.4-3], and 0.8 [0.6-1.3] respectively). Despite the decrease in
ISI, patients with HAIRAN syndrome and acromegaly maintained normal glucose tolerance by adapting
insulin secretion as reflected in the insulinogenic index (106.5 [90.4-127.5] and 49 [24.4-89] in
HAIRAN and acromegaly respectively, versus 46.9 [27.3-66.7] in controls). In contrast, type 2 diabetic
patients failed to adapt and displayed severely hampered insulin secretion (insulinogenic index of 7.6
[3.8-14.7]). Furthermore, the level of the insulinogenic index correlated significantly with duration of
diabetes and HbA1c, which was not the case for the ISI. Insulinoma patients had a decreased
insulinogenic index (38.7 [32-83.8]), leading to impaired glucose tolerance despite normal ISI.
CONCLUSIONS: The data are compatible with the notion that beta-cell function rather than insulin
sensitivity determines the evolution of hyperglycaemia.
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Background: Debate surrounds the relative im-
portance of impaired b-cell secretory function ver-
sus insulin resistance in type 2 diabetes. We there-
fore defined insulin secretion and sensitivity in pa-
tients with impaired glucose homoeostasis of vary-
ing aetiology and duration.
Methods: 126 consecutive patients undergoing
an oral glucose tolerance test (OGTT) between
1999 and 2003 were included. Whole-body insulin
sensitivity index (ISI) and insulinogenic index 
derived from the OGTT were determined in 32
healthy controls, 65 type 2 diabetic patients, 15 pa-
tients with acromegaly, 10 patients with insuli-
noma, and 4 patients with HAIRAN syndrome. 
Results: Median ISI (quartiles Q25–Q75) of
healthy controls and of patients with insulinoma
were similar (3.5 [2.8–5.6] and 3.2 [1.7–4.2] re-
spectively) but significantly decreased in patients
with acromegaly, type 2 diabetes, and HAIRAN
syndrome (2.8 [1.8–3.3], 1.9 [1.4–3], and 0.8
[0.6–1.3] respectively). Despite the decrease in ISI,
patients with HAIRAN syndrome and acromegaly
maintained normal glucose tolerance by adapting
insulin secretion as reflected in the insulinogenic
index (106.5 [90.4–127.5] and 49 [24.4–89] in
HAIRAN and acromegaly respectively, versus 46.9
[27.3–66.7] in controls). In contrast, type 2 dia-
betic patients failed to adapt and displayed severely
hampered insulin secretion (insulinogenic index 
of 7.6 [3.8–14.7]). Furthermore, the level of the
insulinogenic index correlated significantly with
duration of diabetes and HbA1c, which was not 
the case for the ISI. Insulinoma patients had a de-
creased insulinogenic index (38.7 [32–83.8]), lead-
ing to impaired glucose tolerance despite normal
ISI.
Conclusions: The data are compatible with the
notion that b-cell function rather than insulin sen-
sitivity determines the evolution of hypergly-
caemia.
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Patients with type 2 diabetes usually exhibit
both decreased insulin sensitivity and impaired in-
sulin secretion [1, 2]. However, there is debate as
to the relative importance of impaired b-cell secre-
tory function versus insulin resistance in the onset
and progression of diabetes [3]. In the past, a pre-
dominant role has been assigned to insulin resist-
ance in the pathogenesis of impaired glucose ho-
moeostasis, but recently the role of impaired b-cell
function in the pathogenesis of type 2 diabetes has
aroused fresh interest now that a significant reduc-
tion in b-cell mass has been established [4, 5].
The aim of this study was to obtain further
insight into the relative contribution of impaired
insulin secretion in the development of type 2 di-
abetes. We therefore compared the islet secretory
capacity of type 2 diabetic patients with different
groups of patients exhibiting various degrees of
insulin resistance. Included were patients with 
the HAIRAN syndrome (triad of hyperandrogen-
aemia, insulin resistance, and acanthosis nigri-
cans), acromegaly and insulinoma. Patients with
the HAIRAN syndrome exhibit genetically deter-
mined pronounced insulin resistance of the target
tissue [6], whereas patients with acromegaly ex-
hibit acquired decreased insulin sensitivity due to
growth hormone excess [7]. The pathology in 
patients with insulinoma is localised in the pan-
creas but secondary insulin resistance has been 
described [8].
Summary
This work was 
supported by
Swiss National
Science Founda-
tion Grants #
3200–067049.01 &
PP00B-68874/1.
Introduction
Islet secretory capacity in type 2 diabetes 560
Patients
All Caucasian patients undergoing an oral glucose
challenge test (OGTT) between 1999 and 2003 were in-
cluded. Pregnant women were excluded from this study.
The OGTT was performed in 32 healthy individuals, 65
patients with type 2 diabetes, 15 patients with acromegaly,
10 patients with insulinoma, and 4 patients with HAIRAN
syndrome. All medication was stopped 12 hours before the
OGTT. 
Diagnosis of diabetes was based on ADA criteria.
Only type 2 diabetic patients treated by diet or oral antidi-
abetic drugs were included. Patients treated by insulin or
glitazones and with known liver or kidney disease were ex-
cluded. Subjects treated by sulfonylureas were switched to
repaglinide at least five days before the test. Diagnosis of
acromegaly was based on clinical findings, elevated age-
adjusted serum IGF-I concentrations, and/or sustained
elevation of serum GH levels above 1 ng/ml during the
OGTT. One patient with acromegaly and diabetes melli-
tus treated by insulin was excluded. Diagnosis of a GH-
secreting pituitary tumour was histologically confirmed in
all patients. Diagnosis of HAIRAN syndrome was based
on clinical findings including the presence of acanthosis
nigricans and hirsutism as well as demonstration of hyper-
androgenaemia. Diagnosis of insulinoma was based on the
demonstration of endogenous hyperinsulinaemic hypo-
glycaemia and was histologically confirmed in all patients.
Two patients with glucose-sensitive insulinoma and two
with islet cell hyperplasia were excluded from the study
[9]. Due to unspecific autonomous symptoms most of the
healthy individuals were hospitalised for a prolonged fast
to rule out a hypoglycaemic disorder. The 72-hour fast was
negative in all subjects, with adequate suppression of in-
sulin secretion. The OGTT was performed in these sub-
jects (and patients with insulinoma) at the beginning of the
fast to exclude reactive hypoglycaemia; blood samples
were collected over 300 minutes. None of the subjects in-
cluded as controls exhibited evidence of a hypoglycaemic
disorder during the evaluation; patients with confirmed
reactive hypoglycaemia were excluded.
Oral glucose tolerance test
A standard OGTT was performed with a 75-g glu-
cose load after an overnight fast. In the morning, an intra-
venous catheter was inserted into an antecubital vein.
Blood samples were obtained at baseline (mean of two
samples) and 30, 60, 90, and 120 min after the glucose load.
The subjects spent 2 hours in a semirecumbent posture.
Plasma or serum was immediately separated for analysis of
glucose and insulin.
Insulin sensitivity and b-cell function indices
Whole body insulin sensitivity index (ISI) was calcu-
lated by the method of Matsuda and DeFronzo using the
75-g OGTT values as follows [10]:
Whole body ISI = 10’000/square root of [(mean
plasma insulin  mean plasma glucose during OGTT) 
(fasting plasma glucose  fasting plasma insulin)].
The insulinogenic index was defined as the ratio of
the increment of plasma insulin to that of plasma glucose
at 30 min after the glucose load [11, 12].
Laboratory measurements
Venous blood samples were drawn into sodium fluo-
ride-containing tubes for determination of plasma glu-
cose. Plasma glucose was measured by the glucose oxidase
technique (Beckman Analyzer; Beckman, Fullerton, CA,
USA). Insulin was measured in serum samples by solid-
phase radioimmunoassay (CIS Bio international, Oris In-
dustries, Gif-Sur-Yvette, France) with a cross-reactivity of
14% for proinsulin and 0.1% for C-peptide; normal
overnight fasting range provided by the manufacturer was
30 to 138 pmol/L; lower limit of detection 14 pmol/L.
HbA1c was measured by DCA 2000 (Bayer Diagnostics,
Zurich, Switzerland)
Statistics
The statistical difference between the groups of pa-
tients was evaluated by Mann-Whitney U-test, p <0.05
was considered significant. In patients with type 2 dia-
betes, correlation of age, BMI, diabetes duration, and
HbA1c with whole-body ISI and insulinogenic index was
done by Spearman Rank Correlation, these results being
considered significant at p <0.0125 (p <0.05 with a Bon-
ferroni correction for 4 comparisons with control).
Patients and methods
Results
Demographic characteristics and the results of
the OGTT are shown in Table 1. The median age
(quartiles Q25–Q75) of patients with type 2 diabetes
was 62 (51–67) years, BMI was 29 (26–32) kg/m2,
duration of diabetes 5 (2–10) years, and HbA1c 7.3
(6.8–8) %. Patients with type 2 diabetes and
acromegaly were significantly older than healthy
individuals. Patients with diabetes, acromegaly
and insulinoma were overweight and patients with
HAIRAN syndrome obese. In the 32 healthy indi-
viduals, fasting and 2 h plasma glucose concentra-
tions during the OGTT were 4.6 (4.4–5) and 5.6
(4.5–7) mmol/L respectively. In the 65 patients
with type 2 diabetes the fasting plasma glucose
concentration was 8.0 (6.5–9.9) mmol/L; in eight
of them it was normal (i.e. <5.6 mmol/L), in ten
impaired (i.e. 5.6 to 6.9 mmol/L), and in 47 above
6.9 mmol/L. The median 2 h plasma glucose
concentration in type 2 diabetic patients was 
15.5 (12.8–18) mmol/L; two patients had normal
glucose tolerance (i.e. <7.8 mmol/L), one had
impaired glucose tolerance (7.8 to 11.0 mmol/L)
and 62 patients a 2 h plasma glucose concentration
above 11.0 mmol/L. In acromegalic patients 
the fasting plasma glucose concentration was 5.7
(5.5–6); in five of 15 patients it was normal and in
ten impaired. The median 2 h plasma glucose con-
centration in patients with acromegaly was 6.6
(4.6–7.8) mmol/L; 11 patients had normal and four
impaired glucose tolerance. In patients with insuli-
noma the fasting and 2 h plasma glucose concen-
trations were 3.7 (3.1–4.7) and 8.4 (7.8–9.3)
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mmol/L respectively. All 10 insulinoma patients
had fasting plasma glucose concentrations below
5.6 mmol/L. Four insulinoma patients had normal
glucose tolerance, five impaired glucose tolerance,
and one a 2 h plasma glucose concentration above
11.0 mmol/L. In patients with HAIRAN syn-
drome, fasting and 2 h plasma glucose concentra-
tions were 5.0 (4.8–5.5) and 6.7 (6.4–7.6) mmol/L
respectively. 3 out of 4 patients had normal fasting
and 2 h plasma glucose concentrations; and one 
Controls Diabetes Acromegaly Insulinoma HAIRAN
(n = 32) (n = 65) (n = 15) (n = 10) (n = 4)
Female sex (%) 62 35 73 70 100
Age (yr) 37 (30–53) 62 (51–67) 47 (39–67) 62 (54–73) 26 (21–31)
BMI (kg/m2) 22 (20–27) 29 (26–32) 28 (26–29) 27 (24–29) 35 (32–43)
0 min PG (mmol/L) 4.6 (4.4–5) 8.0 (6.5–9.9) 5.7 (5.5–6) 3.7 (3.1–4.7) 5.0 (4.8–5.5)
30 min PG (mmol/L) 7.7 (6.3–9.5) 13.6 (11–14.9) 9.4 (8.4–10.1) 7.2 (6.7–8.8) 9.2 (8.1–10.4)
60 min PG (mmol/L) 7.9 (6.8–8.9) 15.9 (13.7–18.8) 9.9 (7.8–11.3) 8.2 (5.4–9.6) 9.2 (8.9–9.8)
90 min PG (mmol/L) 6.6 (5.9–7.9) 16.5 (13.6–18.5) 8.6 (5.5–9.7) 7.7 (7.2–10.1) 7.8 (7.7–8.7)
120 min PG (mmol/L) 5.6 (4.5–7) 15.5 (12.8–18) 6.6 (4.6–7.8) 8.4 (7.8–9.3) 6.7 (6.4–7.6)
0 min insulin (pmol/L) 106 (63–140) 140 (106–176) 114 (104–170) 163 (144–214) 435 (258–618)
30 min insulin (pmol/L) 487 (293–629) 269 (178–367) 619 (329–968) 493 (370–766) 1657 (1419–1719)
60 min insulin (pmol/L) 448 (355–792) 330 (213–502) 667 (576–993) 377 (369–726) 1903 (1750–2207)
90 min insulin (pmol/L) 460 (280–651) 357 (255–683) 546 (337–688) 598 (391–668) 1650 (1331–1867)
120 min insulin (pmol/L) 273 (147–553) 283 (194–421) 295 (195–736) 409 (187–651) 1393 (688–2056)
Table 1
Demographic charac-
teristics of patients
and results of the
OGTT.
Demographic charac-
teristics and data
from the OGTT in 
32 healthy controls,
65 type 2 diabetic
patients, 15 patients
with acromegaly, 
10 insulinoma pa-
tients and 4 patients
with HAIRAN syn-
drome. Data are
shown as median
and quartiles
(Q25–Q75). PG =
plasma glucose.
Figure 1
Whole-body insulin
sensitivity index and
insulinogenic index.
Whole-body insulin
sensitivity index and
insulinogenic index
derived from the
OGTT in 32 healthy
controls, 65 type 2 
diabetic patients, 
15 patients with
acromegaly, 10 in-
sulinoma patients,
and 4 patients with
HAIRAN syndrome.
Data are shown as
median and quartiles
(Q25–Q75), the indexes
are compared with
healthy controls. 
(* p <0.05, 
** p <0.005).
patient had impaired fasting glucose as well as 
impaired glucose tolerance. Fasting insulin 
levels were significantly higher in patients with dia-
betes (140 [106–176] pmol/L), insulinoma (163
[144–214] pmol/L), and HAIRAN syndrome (435
[258–618] pmol/L) compared with controls (106
[63–140] pmol/L). 30 and 60 min after the oral glu-
cose intake absolute insulin concentrations were
significantly lower in patients with type 2 diabetes
than in healthy controls. 
The whole-body insulin sensitivity indexes
(ISI) and the insulinogenic indexes are shown in
Figure 1. ISI were lower in patients with type 2 di-
abetes, acromegaly, and HAIRAN syndrome than
in younger and leaner healthy individuals, indicat-
ing decreased insulin sensitivity in these groups of
patients. Median ISI was 3.5 (2.8–5.6) in controls
and significantly lower in patients with acromegaly
(2.8 [1.8–3.3]; p <0.005), type 2 diabetes (1.9
[1.4–3]; p <0.0005), and HAIRAN syndrome (0.8
[0.6–1.3]; p <0.005}. The whole-body ISI in pa-
tients with insulinoma was 3.2 (1.7–4.2), not sig-
nificantly lower than that of healthy controls.
The insulinogenic index as an assessment of 
b-cell secretory function was 46.9 (27.3–66.7) in
healthy controls. A higher insulinogenic index of
106.5 (90.4–127.5, p <0.05) was observed in pa-
tients with HAIRAN syndrome. The insulino-
genic indexes in patients with acromegaly and
insulinoma were 49.0 (24.4–89, ns) and 38.7
(32–83.8, ns) respectively. In contrast, the insulino-
genic index of patients with type 2 dia-
betes was dramatically impaired (7.6 [3.8–14.7], 
p <0.0005). 
Within the group of type 2 diabetic patients no
significant correlation was found between patients’
age and whole-body ISI or insulinogenic index (not
shown). The correlation of diabetes duration,
BMI, and HbA1c with both the whole-body ISI 
and the insulinogenic index is shown in Figure 2.
The duration of diabetes did not correlate with
whole-body ISI whereas there was a significant
correlation between diabetes duration and the in-
Figure 2
Patients with type 2
diabetes. Spearman
rank correlation for
whole-body insulin
sensitivity index (ISI)
and insulinogenic
index with duration
of diabetes, BMI, and
HbA1c in 65 patients
with type 2 diabetes. 
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Discussion
Our data illustrate the crucial role of impaired
b-cell function in the pathogenesis of glucose in-
tolerance. Analysing oral glucose tolerance tests
from groups of patients with quite distinct under-
lying diseases, we found that despite higher fasting
insulin levels in all groups of patients with de-
creased insulin sensitivity, insulin secretion during
the OGTT was variable and determined the re-
sultant glucose tolerance status. In patients with
HAIRAN syndrome, for example, a marked de-
crease in insulin sensitivity was compensated by a
marked increase in insulin secretion during the
OGTT and normal glucose tolerance could be
preserved. In contrast, the markedly decreased in-
sulinogenic index in patients with type 2 diabetes
was associated with impaired glucose homoeosta-
sis despite a less pronounced decrease in insulin
sensitivity. On the same lines, absolute insulin lev-
els at 30 and 60 minutes following the glucose in-
take were markedly lower in patients with type 2
diabetes when compared with healthy controls.
Thus, absolute insulin deficiency during the
OGTT in the presence of decreased insulin sensi-
tivity characterised the impaired glucose tolerance
status, whereas normal glucose tolerance could be
preserved by increased (or preserved) insulin se-
cretion.
In patients with type 2 diabetes, longer dura-
tion of diabetes and higher HbA1c levels, but not
age and BMI, correlated with decreased b-cell
function. The decrease in insulin secretion with in-
creasing diabetes duration is in line with the known
decrease in b-cell mass in type 2 diabetes and could
be the rationale for the correlation with higher
HbA1c levels and the observed progressive char-
acter of type 2 diabetes [5, 13]. As well as reflect-
ing decreased insulin secretion, higher HbA1c lev-
els may also be responsible for the decreased se-
cretory capacity of b-cells due to glucotoxicity.
Whatever the relation of HbA1c to b-cell function
turns out to be, our data are in line with the con-
cept of early insulin treatment in poorly controlled
type 2 diabetic patients treated by oral antidiabetic
drugs [14]. Insulin sensitivity indices did not cor-
relate significantly with diabetes duration, HbA1c
or age. As expected, higher BMI values correlated
with lower insulin sensitivity, confirming the well-
recognised reduced insulin sensitivity in over-
weight patients. In contrast, the correlation be-
tween BMI and insulinogenic index was not signif-
icant, indicating absolute insulin deficiency during
the OGTT not only in lean but also in obese type
2 diabetic patients. A limiting factor in our study
was that patients and control subjects were not
matched for age or BMI. However, neither age or
BMI correlated significantly with insulinogenic
index.
A previous study in acromegalic patients
showed that insulin sensitivity is reduced to a sim-
ilar extent in acromegalic patients with normal
glucose tolerance and those with impaired glucose
tolerance or diabetes [15]. However, impaired in-
sulin secretion was found in acromegalic patients
with impaired glucose tolerance or diabetes. Thus,
the degree of impaired b-cell function determined
the glucose tolerance status in patients with
acromegaly in that study. These data were ob-
tained by HOMA model assessment derived from
fasting plasma glucose and serum insulin concen-
trations. Our data derived from the OGTT con-
firm and extend these findings to patients with re-
duced insulin sensitivity due to varying causes.
The aetiology of HAIRAN syndrome is not
known, but a defect “downstream” from the in-
sulin receptor in target tissue has been suggested
[16, 17]. In previous studies the decrease in insulin
sensitivity has been shown to be more pronounced
than in individuals of comparable weight [18]. Our
data show that the marked increase in insulin se-
cretion during the OGTT allows these patients to
preserve normal glucose tolerance and highlight
the fact that normal b-cells are able to compensate
even for marked insulin resistance. 
The decreased insulinogenic index in our
insulinoma patients compared to patients with
acromegaly was associated with an impaired glu-
cose tolerance status despite less reduced insulin
sensitivity. These data highlight the crucial role of
impaired b-cell function in glucose homoeostasis. 
In conclusion, our data illustrate the fact that
impaired b-cell function in the face of decreased
insulin sensitivity determines the degree of glucose
intolerance in patients with reduced insulin sensi-
tivity, i.e. patients with type 2 diabetes, acromegaly,
insulinoma, and HAIRAN syndrome. In patients
with type 2 diabetes a longer duration of diabetes
and higher HbA1c correlated with decreased b-cell
function and absolute insulin deficiency during the
OGTT. Hence, in addition to therapeutic ap-
proaches targeting insulin resistance, other inno-
sulinogenic index (Rho –0.437, p <0.0005), indi-
cating decreased insulin secretion in patients with
a longer duration of diabetes. Higher BMI corre-
lated significantly with lower whole-body ISI (Rho
–0.424, p <0.005), indicating decreased insulin
sensitivity in obese patients. In contrast, BMI did
not correlate with the insulinogenic index. HbA1c
tended to correlate negatively with whole-body ISI
(Rho –0.275, p = 0.03), indicating a trend towards
lower insulin sensitivity in patients with increased
HbA1c. Finally, a significant negative correlation
was found between HbA1c and insulinogenic index
(Rho –0.418, p <0.005), indicating decreased in-
sulin secretion in patients with increased HbA1c.
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vative therapies designed to preserve or even im-
prove functional b-cell mass are desirable.
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